[1]谭碧峰,黄友良,凌 莎,等.基于有序Logistic回归模型的H型高血压疗效影响因素研究[J].医学信息,2022,35(05):69-73.[doi:10.3969/j.issn.1006-1959.2022.05.017]
　TAN Bi-feng,HUANG You-liang,LING Sha,et al.Analysis of Influencing Factors on the Efficacy of H-type hypertension Based on Ordinal Logistic Regression Model[J].Medical Information,2022,35(05):69-73.[doi:10.3969/j.issn.1006-1959.2022.05.017]
点击复制

基于有序Logistic回归模型的H型高血压疗效影响因素研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年05期
页码:
69-73
栏目:
论著
出版日期:
2022-03-01

文章信息/Info

Title:
Analysis of Influencing Factors on the Efficacy of H-type hypertension Based on Ordinal Logistic Regression Model
文章编号:
1006-1959（2022）05-0069-05
作者:
谭碧峰; 黄友良; 凌 莎; 等
（湖南医药学院第一附属医院心血管内科，湖南 怀化 418000）
Author(s):
TAN Bi-feng; HUANG You-liang; LING Sha; et al.
(Department of Cardiovascular,the First Affiliated Hospital of Hunan Medical College,Huaihua 418000,Hunan,China)
关键词:
原发性高血压; H型高血压; 同型半胱氨酸; 氨氯地平片; 马来酸依那普利叶酸片
Keywords:
Essential hypertension; H-type hypertension; Homocysteine; Amlodipine tablets; Enalapril maleate folic acid tablets
分类号:
R544.1
DOI:
10.3969/j.issn.1006-1959.2022.05.017
文献标志码:
A
摘要:
目的 探讨H型高血压的降压疗效及其影响因素，为H型高血压的防治提供科学依据。方法 选取2019年5月-2020年12月在湖南省怀化市辖区社区中重度H型高血压患者300例，采用随机数字表法将研究对象分成综合干预组、治疗组和对照组，每组100例，分别予以口服马来酸依那普利叶酸片+氨氯地平联合行为生活方式综合干预、马来酸依那普利叶酸片+氨氯地平、马来酸依那普利+氨氯地平治疗6个月，观察用药前后各组患者的血压及血浆同型半胱氨酸（Hcy）水平，并对年龄、性别、分组干预方式、生活水平、高血压家族史、吸烟、饮酒、饮食习惯、工作性质、是否患肾脏疾病、不良反应、用药依从性进行有序多分类Logistic回归分析。结果 治疗6个月后，综合干预组、治疗组及对照组的降压总有效率分别为92.71%，90.22%和91.11%，差异无统计学意义（P＞0.05）；三组收缩压（SBP）、舒张压（DBP）较治疗前均降低，差异有统计学意义（P＜0.05）；综合干预组、治疗组血浆Hcy水平较治疗前降低（P＜0.05）；H型高血压患者疗效影响因素的单因素回归分析显示，分组干预方式、吸烟、是否患肾脏疾病、用药依从性与H型高血压疗效有关；多因素有序Logistic回归分析显示，分组干预方式、是否患肾脏疾病、用药依从性是H型高血压疗效的独立影响因素。结论 三组H型高血压患者均能有效控制血压，不同治疗及干预方式、是否患肾脏疾病、用药依从性是影响H型高血压疗效的独立相关因素。
Abstract:
Objective To investigate the antihypertensive effect of H-type hypertension and its influencing factors, so as to provide scientific basis for the prevention and treatment of H-type hypertension.Methods A total of 300 patients with moderate to severe H-type hypertension in the community of Huaihua City, Hunan Province from May 2019 to December 2020 were selected and randomly divided into a comprehensive intervention group, a treatment group and a control group, with 100 cases in each group; and they were treated with enalapril maleate folic acid tablets combined with amlodipine, enalapril maleate folic acid tablets combined with amlodipine, enalapril maleate folic acid tablets combined with amlodipine and enalapril maleate combined with amlodipine for 6 months, respectively. The blood pressure and plasma homocysteine (Hcy) levels were observed before and after treatment. The age, gender, group intervention, living standards, family history of hypertension, smoking, drinking, eating habits, nature of work, whether suffering from kidney disease, adverse reactions and medication compliance were analyzed by ordinal logistic regression.Results After 6 months of treatment, the total effective rates of comprehensive intervention group, treatment group and control group were 92.71%, 90.22% and 91.11%, respectively, and the difference was not statistically significant (P>0.05); the systolic blood pressure (SBP) and diastolic blood pressure (DBP) of the three groups were lower than those before treatment, and the difference was statistically significant (P<0.05); the plasma Hcy levels in the comprehensive intervention group and the treatment group were significantly lower than those before treatment (P<0.05). The univariate regression analysis of the influencing factors on the efficacy of H-type hypertension showed that the grouping intervention, smoking, renal disease and medication compliance were related to the efficacy of H-type hypertension. The multivariate ordered logistic regression analysis showed that the grouping intervention, renal disease and medication compliance were independent factors affecting the efficacy of H-type hypertension.Conclusion Three groups of patients with H-type hypertension can effectively control blood pressure, different treatment and intervention methods, whether suffering from kidney disease, medication compliance are independent related factors affecting the efficacy of H-type hypertension.

参考文献/References:

[1]李建平,卢新政,霍勇,等.H型高血压诊断与治疗专家共识[J].中华高血压杂志,2016,24(2):123-127.[2]孙宁玲,李建平,卢新政,等.H型高血压诊断标准依据解读[J].中华高血压杂志,2017,25(6):508-510.[3]李庆辉,谭碧峰,杨天伦,等.氨氯地平联合依那普利/叶酸对H型高血压的疗效及其与EL和APN的关系[J].中国临床研究,2016,29(5):594-597.[4]中国高血压防治指南修订委员会.中国高血压防治指南(2018年修订版)[J].中国心血管杂志,2019,24(1):24-56.[5]李建平.关于高血压患者同型半胱氨酸干预切点的探讨[J].中国实用内科杂志,2017,37(10):895-897[6]马孝天,余书康,李贯清.H型高血压与腔隙性脑梗死患者血流动力学变化的相关研究[J].医学信息,2018,31(24):78-81.[7]邱爽,杨波,平海芹,等.叶酸联合降压药预防H型高血压患者脑卒中的系统分析[J].中国心血管病研究,2015,13(8):723-726.[8]Qin X,Li Y,Sun N,et al.Elevated homocysteine concentrations decrease the antihypertensive effffect of angiotensin convertingenzyme inhibitors in hypertensive patients[J].Arterioscler Thromb Vasc Biol,2017,37(1):166-172.[9]韩亚州,闫军.马来酸依那普利叶酸片治疗H型原发性高血压的疗效与安全性[J].中国实用神经疾病杂志,2017,20(3):125-127.[10]赵自瑞.马来酸依那普利叶酸片对H型高血压左心室肥厚患者血浆同型半胱氨酸浓度、心脏结构及功能的影响[J].岭南心血管病杂志,2017,23(5):596-599.[11]薛军.马来酸依那普利叶酸片治疗H型高血压伴糖尿病的疗效及对糖代谢、肾功能和血清同型半胱氨酸的影响[J].中国药业,2018,27(3):61-63.[12]蒋海霞.马来酸依那普利叶酸片治疗H型原发性高血压的疗效和安全性分析[J].中国药物与临床,2019,19(4):647-649.[13]尚晖,李勋.H型高血压患者颈动脉粥样硬化相关危险因素分析[J].中国动脉硬化杂志,2019,27(11):969-974,984.[14]张艳霞,刘玉清,马朝阳,等.H型高血压患者血清Hcy、尿微量白蛋白/肌酐比值与血压变异及靶器官功能受损的关系[J].中国循证心血管医学杂志,2020,12(3):333-336.[15]宋婷婷,刘丽,付志强,等.H型高血压合并射血分数保留心力衰竭患者发生颈动脉硬化的危险因素分析[J].中国循证心血管医学杂志,2020,12(4):446-448,451.[16]李理,王媛,王垚,等.H型高血压患者吸烟与血清同型半胱氨酸的相关性研究[J].中国临床保健杂志,2021,24(1):67-69.[17]覃显波,黄晓雅,林金环.H型高血压患者肾损害危险因素的多因素Logistic回归分析[J].内科,2020,15(1):39-41,44.[18]唐岚,周礼清,王人佩,等.叶酸联合维生素B6对老年H型高血压患者高同型半胱氨酸血症的疗效观察[J].山西医药杂志,2016,45(4):3.[19]欧永强,王维箭,赵鹏.血清同型半胱氨酸水平与H型高血压伴颈动脉粥样硬化患者炎症反应及斑块稳定性的关系[J].中国老年学杂志,2019,39(8):3614-3617.[20]甘家红,朱黎黎.血清Hcy水平变化对H型高血压患者肾损害的预测价值[J].国际检验医学杂志,2019,40(15):1872-1874.

相似文献/References:

[1]段淑婷,王义围,王兆鹏.高血压病合并糖调节受损患者血压变异性的相关研究[J].医学信息,2018,31(05):11.[doi:10.3969/j.issn.1006-1959.2018.05.004]
　DUAN Shu-ting,WANG Yi-wei,WANG Zhao-peng.Study on Blood Pressure Variability in Patients with Hypertension Complicated with Impaired Glucose Regulation[J].Medical Information,2018,31(05):11.[doi:10.3969/j.issn.1006-1959.2018.05.004]
[2]熊依良.奥美沙坦酯氢氯噻嗪片治疗轻中度原发性高血压的疗效及安全性分析[J].医学信息,2018,31(19):142.[doi:10.3969/j.issn.1006-1959.2018.19.043]
　XIONG Yi-liang.Efficacy and Safety of Olmesartan Medoxomil and Hydrochlorothiazide Tablets in the Treatment of Mild to Moderate Essential Hypertension[J].Medical Information,2018,31(05):142.[doi:10.3969/j.issn.1006-1959.2018.19.043]
[3]李信明,刘春梅,任正强,等.供需平衡视角下原发性高血压的病机与防治[J].医学信息,2018,31(19):182.[doi:10.3969/j.issn.1006-1959.2018.19.058]
　LI Xin-Ming,LIU Chun-Mei,REN Zheng-Qiang,et al.Pathogenesis and Prevention of Essential Hypertension from the Perspective of Supply and Demand Balance[J].Medical Information,2018,31(05):182.[doi:10.3969/j.issn.1006-1959.2018.19.058]
[4]马孝天,余书康,李贯清.H型高血压与腔隙性脑梗死患者血流动力学变化的相关研究[J].医学信息,2018,31(24):78.[doi:10.3969/j.issn.1006-1959.2018.24.020]
　MA Xiao-tian,YU Shu-kang,LI Guan-qing.Correlation between Hemodynamic Changes in Patients with H-type Hypertension and Lacunar Infarction[J].Medical Information,2018,31(05):78.[doi:10.3969/j.issn.1006-1959.2018.24.020]
[5]穆大明.厄贝沙坦氢氯噻嗪与福辛普利治疗原发性高血压的疗效观察[J].医学信息,2019,32(03):151.[doi:10.3969/j.issn.1006-1959.2019.03.049]
　MU Da-ming.Efficacy of Irbesartan Hydrochlorothiazide and Fosinopril in the Treatment of Essential Hypertension[J].Medical Information,2019,32(05):151.[doi:10.3969/j.issn.1006-1959.2019.03.049]
[6]潘建鑫.高血压患者血小板/淋巴细胞比值与颈动脉粥样硬化的相关性分析[J].医学信息,2020,33(05):77.[doi:10.3969/j.issn.1006-1959.2020.05.023]
　Pan Jianxin.Correlation analysis of platelet/lymphocyte ratio and carotid atherosclerosisin patients with primary hypertension[J].Medical Information,2020,33(05):77.[doi:10.3969/j.issn.1006-1959.2020.05.023]
[7]谢祥红.AngⅡ、ET-1对高血压患者病情发生发展的影响[J].医学信息,2020,33(16):75.[doi:10.3969/j.issn.1006-1959.2020.16.023]
　XIE Xiang-hong.Effects of AngⅡ and ET-1 on the Occurrence and Development of Hypertension Patients[J].Medical Information,2020,33(05):75.[doi:10.3969/j.issn.1006-1959.2020.16.023]
[8]刘 柳,吕风华.原发性高血压患者脉压与左心室肥厚及射血分数保留的心衰的相关性[J].医学信息,2021,34(01):112.[doi:10.3969/j.issn.1006-1959.2021.01.029]
　LIU Liu,LYU Feng-hua.Correlation of Pulse Pressure with Left Ventricular Hypertrophy and Heart Failure with Preserved Ejection Fraction in Patients with Essential Hypertension[J].Medical Information,2021,34(05):112.[doi:10.3969/j.issn.1006-1959.2021.01.029]
[9]魏 炜.奥美沙坦酯和坎地沙坦酯治疗原发性高血压的效果比较[J].医学信息,2021,34(14):160.[doi:10.3969/j.issn.1006-1959.2021.14.045]
　WEI Wei.Comparison of the Effects of Olmesartan Medoxomil and Candesartan Cilexetil in the Treatment of Essential Hypertension[J].Medical Information,2021,34(05):160.[doi:10.3969/j.issn.1006-1959.2021.14.045]
[10]郑艳芳,郭军霞,张永春.原发性高血压合并阵发性心房颤动的危险因素分析[J].医学信息,2021,34(22):51.[doi:10.3969/j.issn.1006-1959.2021.22.014]
　ZHENG Yan-fang,GUO Jun-xia,ZHANG Yong-chun.Risk Factors Analysis of Essential Hypertension Complicated with Paroxysmal Atrial Fibrillation[J].Medical Information,2021,34(05):51.[doi:10.3969/j.issn.1006-1959.2021.22.014]

更新日期/Last Update: 1900-01-01